ARCHIVES

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

This article is from The Cancer Letter archive.

Vol. 26 No. 11 | November 28, 2003

Download PDF Visit The Full Archive

Related Articles

Wallen Pleads Guilty To Lesser Charges, To Pay $20,000 to CALGB, FDA

August 31, 1984

Committee To Set Research Agenda On Breast Cancer. Justice Department Appeals Injunction On Stem Cell Research

September 3, 2010

Celebrex Studied As Potential Prevention Of Lung Cancer In High-Risk Populations

August 31, 2001

Centers: Bookman Leaves Fox Chase for Arizona

September 11, 2009

RFAs available: Chemoprevention Clinical Trials

July 22, 1994

Zaltrap Economics 101: The Pricing And Repricing of an Expensive Drug

November 16, 2012